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Editorial on the Research Topic
Molecular, Cellular and Model Organism Approaches for Understanding the Basis of
Neurological Disease
Next-generation sequencing technologies have resulted in remarkable increases in our
understanding of human neurological disorders through the identification of disease-causing or
protective sequence variants. However, in many cases, newmolecular, cellular, and whole-organism
models are required to understand how changes at the DNA, RNA, or protein level affect neuronal
and synaptic function. In turn, these models may enable understanding of key disease processes
and the identification of new targets for the medicines of the future. What is also evident is the
high quality and impact of the research conducted in this field. This is reflected in the reviews and
research articles in this Special Issue entitled “Molecular, cellular and model organism approaches
for understanding the basis of neurological disease.”
Mutation and gene discovery in neurological diseases has recently been transformed by large-
scale DNA sequencing approaches coupled with stringent variant filtering. This is particularly
true of intellectual disability, characterized by significantly impaired intellectual and adaptive
function. Long et al. and Kalscheuer et al. highlight the utility of this methodology by resolving
two families with X-linked intellectual disability caused by mutations in ARHGEF9 and IQSEC2,
which both encode neuronal GDP–GTP exchange factors. One important aspect of these studies
was functional validation of the pathogenic variants using molecular modeling, phosphoinositide
binding, gephyrin clustering, or GDP–GTP exchange activity. By contrast, Krüger et al. reported
on the use of panel sequencing to study a cohort of 80 German patients with Amyotrophic lateral
sclerosis (ALS), a rapidly progressive, fatal neurological disease that causes degeneration of motor
neurones. This approach allowed deep sequencing of 39 confirmed ALS genes and candidate genes,
as well as 238 genes associated with other neurodegenerative diseases. They identified 79 rare
potentially pathogenic variants in 27 ALS-associated genes, as well as pathogenic hexanucleotide
repeats in C9orf72. Based on this study, the authors recommend two-staged genetic testing for
ALS in patients with familial and sporadic ALS, comprising C9orf72 repeat analysis followed by
comprehensive panel sequencing.
It is also important to remember that not all rare genetic variants are disease causing.
Nixon-Abell et al. reported the detailed molecular and cellular characterization of a protective
variant in LRRK2, encoding leucine-rich repeat kinase 2 (LRRK2) which is intimately associated
with the pathogenesis of Parkinson’s disease. Importantly, the p.R1398H variant affects GTPase
function, axon outgrowth, and Wnt signaling in a manner opposite to pathogenic LRRK2
Harvey and Harvey Editorial: Understanding the Basis of Neurological Disease
mutations. The authors concluded that LRRK2-mediated Wnt
signaling and GTPase function are fundamental in conferring
disease susceptibility, and that this has clear implications for
future therapeutic interventions in Parkinson’s disease.
Sophisticated cellular models of disease are increasingly
vital as high-throughput screening tools for recreating events
at normal and disrupted synapses in vitro. Kuenzel et al.
reported a new tool for screening of in vitro neurotoxicity
(NT) and developmental neurotoxicity (DNT) mediated by
inhibitory γ-aminobutyric acid type A (GABAA) and glycine
receptors (GlyRs). They generated a human pluripotent stem
cell line (NT2) that stably expresses YFPI152L, a halide-sensitive
variant of YFP, which allows for fluorescence-based functional
analysis of Cl− channels. Importantly, upon stimulation with
retinoic acid, these NT2 cells undergo neuronal differentiation,
allowing pharmacological and toxicological evaluation of native
GABAARs and GlyRs at different developmental stages. By
contrast, Dixon et al. reported an “artificial synapse” system—
a neuron-HEK293 cell co-culture technique for generating
inhibitory synapses incorporating defined combinations of wild-
type or mutant GABAAR or GlyR subunits. As well as allowing
control over the subunit composition of the GlyRs under study,
the electrotonically compact shape of HEK293 cells combined
with rapid agonist application allows IPSC waveforms to be
resolved with high fidelity using electrophysiology.
The role of the GlyR M3-M4 intracellular domain in health
and disease was also reviewed by Langlhofer and Villmann
who comprehensively documented molecular determinants
of phosphorylation, intracellular sorting, protein–protein
interactions, subunit topology, and modulation by G proteins,
ethanol, and cannabinoids. Barral and Kurian also reviewed
the current and future potential of patient-derived induced
pluripotent stem cells (iPSCs) in the field of childhood
neurological disorders. Importantly, iPSCs can now be routinely
differentiated into specific neuronal subtypes which represent
valuable in vitro models of disease. They are also vital tools
for testing existing drugs with repurposing potential, or novel
compounds and gene therapies, which then can be translated to
clinical practice. Imaging also has a key role to play in diagnosis
of disease. Poutiainen et al. reviewed advances in non-invasive
imaging techniques such as positron emission tomography
(PET) and prospective biomarkers for the diagnosis of multiple
sclerosis.
Whole-organism in vivo models also continue to make
an impact in this field. Kozol et al. and Ogino and Hirata
reviewed the many advantages of zebrafish in the study
of neurological disease. Validation of new disease genes
and mutations is now possible through CRISPR/Cas9
mutagenesis of zebrafish gene orthologs, which rapidly creates
new disease models which are amenable to phenotyping
and high-throughput drug screening. Watanabe et al.
also highlighted the use of sophisticated mouse models,
showing how doxycycline-sensitive, Cre-mediated gene
ablation of NMDA receptors in hippocampal excitatory
neurons results in neurodegeneration in aging mice.
This study highlighted the potentially damaging effects
of long-term administration of NMDAR antagonists for
therapeutic purposes. Lykhmus et al. used an acute model
of LPS-induced neuroinflammation in mice and an in
vitro model in cultured glioblastoma U373 cells to study
neuroinflammation, which accompanies and often precedes
the development of neurodegenerative pathologies such as
Parkinson’s and Alzheimer’s diseases. They found that acute
LPS-induced inflammation induced the cholinergic anti-
inflammatory pathway in the brain, with down-regulation
of α7 subunit-containing nAChRs limiting these effects.
Curiously, nAChR α7 subunit-specific antibodies aggravated
neuroinflammation, by inducing the pro-inflammatory
interleukin-6 and dampening anti-inflammatory miRNAs.
However, the authors also highlighted that nAChR α7-specific
antibodies may protect brain mitochondria and decrease the
levels of pro-apoptotic miRNAs, preventing LPS-induced
neurodegeneration.
We thank all contributors for their interesting and informative
articles and the reviewers for their constructive and thoughtful
suggestions.
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